

26th October, 2016

The Dy. General Manager (Listing Dept.)
BSE Limited.,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Submission / Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (“Listing Regulations”) of Financial Results (Standalone and Consolidated) for the quarter and half year ended on 30th September, 2016.

In continuation to our letter dated 10th October, 2016 intimating about the Board meeting to be held on Wednesday, 26th October, 2016, we would like to inform that the Board meeting commenced at 02:30 pm and concluded at 05:00 pm, and it considered and approved the following:

1. Audited Standalone Financial Results along with audit report thereon and Unaudited Consolidated Financial Results alongwith the limited review report of the Company for the quarter and half year ended on 30th September, 2016 as per Regulation 33 of Listing Regulations.

In terms of Regulation 47 of the Listing Regulations read with relevant SEBI Circular, the Company will publish Extract of the Unaudited Consolidated Financial Results for the quarter and half year ended on 30th September, 2016. Both Standalone and Consolidated Financial Results will be available at Company’s website www.torrentpharma.com.

2. Press Release on Financial Results including performance highlights as being submitted to the media.

The above is enclosed herewith for your information and record.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY

TORRENT PHARMACEUTICALS LIMITED

CIN : L24230GJ1972PLC002126

Encl.: As above